PIPELINES

 

AP-03

AP-03 is a first-in-class invadopodia-targeted monoclonal antibody that specifically blocks the ability of the invadopodial surface protein MIR-03 to activate extracellular proteases, thereby inhibiting the proteolytic function of invadopodia and cancer cell invasion (Figure 1). Antapodia Therapeutics has conducted compelling proof-of-concept studies to demonstrate that systemic administrations of AP-03 could effectively inhibit the development of distant metastases in gastric cancer (Figure 2) as well as lung cancer dissemination, thereby substantially extending survival (Figure 3). The company is now testing AP-03 in clinically relevant PDX metastasis models to further verify its therapeutic potential, as well as conducting PK/PD and toxicity studies in non-human primates to enable its IND application.

Figure 1.  AP-03 inhibits collagen degradation, invadopodia formation, and cancer cell invasion

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival(metastasis control rate = 79.4%; survival extension = 28%).

GAC: gastric adenocarcinoma; NSCLC: non-small cell lung cancer.

Figure 2.  Systemic AP-01 therapy inhibits gastric cancer metastasis and lengthens survival

Metastasis control: 86%; survival extension 169%

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival(metastasis control rate = 79.4%; survival extension = 28%).

GAC, gastric adenocarcinoma; IV, intravenous; wk, week; BLI, bioluminescence. Red arrows indicate the time of AP-03 injections. Note that all the mice treated with control IgG died before 6 weeks following the initiation of the treatments.

Figure 3.  Systemic AP-03 therapy inhibits lung cancer dissemination and lengthens survival

Tumor control: 85%; survival extension 200%

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival(metastasis control rate = 79.4%; survival extension = 28%).

NSCLC, non-small lung cancer; IV, intravenous; wk, week; BLI, bioluminescence. Red arrows indicate the time of AP-03 injections.

Logo_vertical_light.png

Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.

Search